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Transmembrane signaling by the epidermal growth
factor receptor (EGFR) involves ligand-induced
dimerization and allosteric regulation of the intracel-
lular tyrosine kinase domain. Crystallographic
studies have shown how ligand binding induces
dimerization of the EGFR extracellular region but
cannot explain the ‘‘high-affinity’’ and ‘‘low-affinity’’
classes of cell-surface EGF-binding sites inferred
from curved Scatchard plots. From a series of crystal
structures of the Drosophila EGFR extracellular
region, we show here how Scatchard plot curvature
arises from negatively cooperative ligand binding.
The first ligand-binding event induces formation of
an asymmetric dimer with only one bound ligand.
The unoccupied site in this dimer is structurally
restrained, leading to reduced affinity for binding of
the second ligand, and thus negative cooperativity.
Our results explain the cell-surface binding charac-
teristics of EGF receptors and suggest how
individual EGFR ligands might stabilize distinct
dimeric species with different signaling properties.
INTRODUCTION
Receptor tyrosine kinases (RTKs) in the epidermal growth factor
receptor (EGFR/ErbB/HER) family play pivotal roles in animal
development and in disease (Hynes and MacDonald, 2009;
Jorissen et al., 2003; Shilo, 2005). In particular, EGFR and
ErbB2/HER2/Neu are mutated or overexpressed in several
human cancers (Hynes and MacDonald, 2009; Sharma et al.,
2007). These facts have motivated the development of tyrosine
kinase inhibitors (erlotinib, gefitinib, and lapatinib) and mono-
clonal antibodies (including trastuzumab and cetuximab) used
to target these receptors in cancer patients, plus intensive efforts
to understand their signaling mechanisms.
Although it is well known that EGF induces dimerization of
its receptor (Yarden and Schlessinger, 1987), precisely how
this leads to EGFR activation is not yet fully understood568 Cell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc.(Jura et al., 2009; Lemmon, 2009). Crystal structures of unligated
ErbB receptor extracellular regions (Ferguson, 2008) and of
ligand-bound dimers of the EGFR extracellular region (Garrett
et al., 2002; Ogiso et al., 2002) have revealed large conforma-
tional changes that are crucial for ligand-induced dimerization.
A key ‘‘dimerization arm’’ is buried by an intramolecular ‘‘tether’’
in the unligated receptor (Bouyain et al., 2005; Cho and Leahy,
2002; Ferguson et al., 2003) and becomes exposed in the
ligand-bound ‘‘extended’’ configuration, allowing it to mediate
the majority of receptor/receptor interactions in the dimer
(Garrett et al., 2002; Ogiso et al., 2002).
Disappointingly, all binding/dimerization models derived from
the crystal structures of EGFR extracellular regions (Burgess
et al., 2003; Klein et al., 2004) fail to account for the characteristic
curvilinear (concave-up) Scatchard plots that were first described
for EGF binding to its cell-surface receptor 30 years ago (Magun
et al., 1980; Shoyab et al., 1979). These concave-up Scatchard
plots can signify either negative cooperativity or heterogeneity
of binding sites. Traditionally, the latter interpretation has been
assumed for EGFR—leading to the notion that this single gene
product gives rise to independent (and much-discussed) ‘‘high-
affinity’’ (KD 0.3 nM) and ‘‘low-affinity’’ (KD 2 nM) classes of
EGF-binding site at the cell surface (Schlessinger, 1986). The
molecular differencesbetween theseproposedclassesofbinding
site, and how they could arise from a single EGF receptor protein,
are far fromclear.Recentdataargue thatScatchardplot curvature
reflects negative cooperativity rather than distinct classes of
binding site (Macdonald and Pike, 2008; Macdonald-Obermann
and Pike, 2009). Neither view can be reconciled, though, with
published biophysical studies of the isolated human EGFR extra-
cellular region (s-hEGFR), and several reports have invoked
a requirement for other unknown cellular components (Klein
et al., 2004; Wofsy et al., 1992).
Here we describe the structural basis for negatively coopera-
tive ligand binding to an isolated EGFR extracellular region,
revealing how this can occur in the absence of other cellular
components—as an intrinsic property of the receptor. Our
studies exploit the finding that—unlike its human counterpart—
the EGF receptor from Drosophila melanogaster (dEGFR) retains
negative cooperativity in ligandbinding (andconcave-upScatch-
ard plots) when its extracellular region is studied in isolation.
Because the dEGFR extracellular region (s-dEGFR) retains key
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Figure 1. An Asymmetric Ligand-Induced s-dEGFRDV Dimer
(A) The (SpitzEGF)2,(s-dEGFRDV)2 dimer is asymmetric. Domains I, III, and IV are blue, yellow, and red, respectively. Domain II is green in the left-hand molecule
(IIL) and dark gray in the right-handmolecule (IIR). Bound ligand ismagenta. The domain II dimerization arm is labeled. An asteriskmarks the amino-terminal part of
domain II where asymmetry is most evident.
(B) Structure (PDB ID code 1IVO) of the symmetric EGF-induced dimer of the human EGFR extracellular region (s-hEGFR) lacking domain IV (Ogiso et al., 2002),
colored as in (A).
(C) Overlay of the left (green) and right (red) molecules from the s-dEGFRDV dimer, using domain I as reference. A double-headed curved arrow illustrates
‘‘wedging’’ apart of domains I and III in the green molecule compared with the red molecule, breaking direct domain I/III interactions detailed in Figure S1,
and altering the domain II conformation so that the dimerization arm is substantially reoriented.
(D) Overlay of the right-handmolecule from the asymmetric s-dEGFRDV dimer (red) on unligated s-dEGFRDV (cyan) fromPDB ID code 3I2T (Alvarado et al., 2009),
using domain I as reference.
(E) Overlay of the two receptor molecules in the human (EGF)2,(s-hEGFRDIV)2 dimer. See Table S1 for crystallographic statistics.ligand-binding characteristics previously seen only for intact EGF
receptors in cell membranes, it provides a unique opportunity to
understand their structural basis. We describe crystal structures
of s-dEGFR bound to its growth factor ligand Spitz, which show
howoccupyingonebinding site in a receptor dimer impairs ligand
binding to the second site in an asymmetric complex—providing
a structural explanation for the origin of negative cooperativity.
Our structures allow us, in effect, to visualize directly the long-
sought-after high-affinity and low-affinity ligand-binding sites of
an EGFR family member (although they are not independent).
These findings also have important implications for under-standing how EGFR ligands with different receptor-binding affin-
ities may elicit distinct sets of cellular responses.
RESULTS AND DISCUSSION
The Ligand-Induced Dimer of the dEGFR Extracellular
Region Is Asymmetric
The key to understanding negatively cooperative growth factor
binding to the Drosophila EGF receptor lies in the asymmetry of
the Spitz-induced s-dEGFR dimer shown in Figure 1A.We crystal-
lized a form of s-dEGFR bound to the EGF-like domain of SpitzCell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc. 569
(SpitzEGF; encompassing residues 48–105), and determined its
structure to 3.2 A˚ resolution (see Table S1 available online). The
overall domain architecture of s-dEGFR is very similar to that in
human EGFR (Burgess et al., 2003), with which it shares 39%
sequence identity over domains I–IV. The ‘‘solenoid’’ domains I
and III contact the same bound growth factor molecule in ligand-
stabilized dimers of Drosophila (Figure 1A) and human (Figure 1B)
sEGFR. Domains II and IV are cysteine-rich laminin-related
domains, and domain II harbors the dimerization arm that drives
core receptor/receptor contacts in both dimers. The complete
dEGFR extracellular region contains an additional cysteine-rich
domain of 150 amino acids that is absent in hEGFR (domain V,
which resembles domains II and IV). Previous small-angle X-ray
scattering studies of s-dEGFR showed that domain V projects as
a linear extension from the domain IV C terminus (Alvarado et al.,
2009). Removing domain V (to yield s-dEGFRDV) was essential
for crystallization of the ligand,receptor complexes reported here.
Whereas ligand-bound dimers of the human EGFR extracellular
region (Figure 1B) are symmetric, the (SpitzEGF)2,(s-dEGFRDV)2
dimer shows clear asymmetry (Figure 1A). This asymmetry is
most evident at the dimer interface, close to the domain II amino
terminus (markedwith an asterisk in Figure 1A). Indeed, significant
differences in the relationships between domains I, II, and III are
seen when the two subunits from the s-dEGFRDV dimer are over-
laid in Figure 1C (the left-hand molecule from Figure 1A is colored
green, and the right-hand molecule is red)—yielding an overall
root-mean-square deviation (rmsd) in Ca positions of 3.4 A˚.
Figure 1D further shows that the right-hand molecule of the
(SpitzEGF)2,(s-dEGFRDV)2 complex (red) closely resembles the
unligated s-dEGFRDV structure (cyan) that we recently described
(Alvarado et al., 2009), overlaying with a Ca position rmsd of just
1.3 A˚. Ligandbinding has therefore not altered the domain I/III rela-
tionship in the right-handmoleculeof Figure1A.Direct interactions
between these two ligand-binding domains that stabilize the
unligated conformation are retained—but remodeled in detail
(Figure S1). By contrast, upon binding to the left-hand subunit
(green in Figure 1C), SpitzEGF ‘‘wedges’’ itself between the two
ligand-binding domains and pushes them apart, as indicated by
the double-headed arrow in Figure 1C, to break the direct domain
I/III interactions seen in unligated s-dEGFRDV (Figures S1A and
S1C). Moreover, separating domains I and III with this ‘‘ligand
wedge’’ distorts domain II (which connects them) and forces
a substantial reorientation of the dimerization arm (Figure 1C). By
distorting domain II in only one of the two s-dEGFRDV molecules
in the dimer (the left-hand one), ligand binding induces themarked
asymmetryseen inFigure1Aandallowsformationofamoreexten-
sive (asymmetric) dimer interface than would otherwise be
possible. Indeed,asdescribed indetail later, theasymmetricdimer
interface in Figure 1A buries a total surface area of 3396 A˚2, some
33%greater than the 2553 A˚2 buried between the two nearly iden-
tical subunits of the symmetric human s-EGFR dimer (which over-
lay with a Ca position rmsd of just 0.8 A˚, as shown in Figure 1E).
Inequivalence of the Two Ligand-Binding Sites in the
dEGFR Dimer Suggests Cooperativity
One important consequence of asymmetry in the (SpitzEGF)2,
(s-dEGFRDV)2 dimer is that the two ligand-binding sites differ
significantly from one another (Figure 2A), whereas the two570 Cell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc.binding sites in the human s-EGFRDIV dimer are almost identical
(Figure 2B). Differences between the two ligand-binding sites in
the (SpitzEGF)2,(s-dEGFRDV)2 dimer are most apparent where
SpitzEGF contacts domain I. Figure 2Ashows the twos-dEGFRDV
molecules from Figure 1A overlaid using the bound ligand as
reference (the left-handmolecule fromFigure 1A is coloredgreen,
and the right-handmolecule is red). By wedging domains I and III
apart, SpitzEGF has shifted domain I of the greenmolecule toward
the top left corner of the figureby3–5 A˚ comparedwith its position
in the red s-dEGFRDV molecule, and has displaced the N-
terminal a helix of domain I by 7 A˚ along its axis (see green
arrows in Figure 2A). Because of this shift in domain I position,
its interactions with SpitzEGF are significantly altered in detail
when the red and green sites are compared (upper inset in
Figure 2A), although they involve similar sets of dEGFR residues.
The domain III/SpitzEGF interface is less altered between the
two binding sites (lower inset of Figure 2A). The change in
domain III position with respect to bound ligand is small, and is
mostly compensated for by small adjustments in rotamer posi-
tions of interfacial side chains. In a few cases, dEGFR side chains
appear to replace one another functionally in the two domain
III/SpitzEGF interfaces. For example, in the interface between
SpitzEGF and the green binding site, the H433 side chain (under-
lined in Figure 2A) assumes the position occupied by E460 in the
red binding site. Similarly, E400 substitutes spatially for S401
when the SpitzEGF-binding surfaces of the green and red binding
sites are compared (Figure 2A, lower inset).
These differences in the way that SpitzEGF interacts with the
two binding sites in the asymmetric s-dEGFRDV dimer can
also be thought of as a displacement of ligand on the domain I
and III surfaces, as illustrated in Figure S2. In this view, it is clear
that the SpitzEGF A, B, and C loops all make significantly different
contacts with the receptor in the two binding sites. Only the loca-
tion of the SpitzEGF C terminus on domain III is fixed between the
two sites (Figure S2B), consistent with previous studies that
point to the C termini of other EGF-like ligands as major determi-
nants of binding affinity (Groenen et al., 1994).
As mentioned above, the red binding site in Figure 2A reflects
s-dEGFRDV in a conformation that is unchanged from the unli-
gated receptor (Figure 1D), whereas forming the green binding
site requires the ligand to wedge apart domains I and III. When
SpitzEGF binds to the green (wedged-open) site, a total surface
area of 4030 A˚2 is buried, compared with just 3730 A˚2 in the red
(unaltered) site. Moreover, binding to the green site involves
four additional predicted hydrogen bonds between ligand and
receptor (an increase of 16% over the red site). Thus, the green
s-dEGFRDV molecule shown in Figure 1C and Figure 2A (the
left-hand subunit in Figure 1A) has characteristics expected for
a higher-affinity site. By contrast, the red s-dEGFRDV molecule
in Figure 1C and Figure 2A (the right-hand subunit in Figure 1A)
appears to be restrained in an unligated-like conformation, which
may in turncompromise ligandbindingso that this site hasa lower
binding affinity.
Negatively Cooperative Ligand Binding
Can Be Recapitulated with s-dEGFR
The structural inequivalence of the two SpitzEGF-binding sites in
Figure 1 and Figure 2 prompted us to ask whether distinct
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Figure 2. The Ligand-Binding Sites in the (SpitzEGF)2,(s-dEGFRDV)2 Dimer Are Inequivalent
(A) Overlay of the two ligands (gray) in the (SpitzEGF)2,(s-dEGFRDV)2 dimer, illustrating differences in their binding sites (see also Figure S2). The green structure
corresponds to the left-hand molecule in Figure 1A, and the red structure to the right-hand molecule. Green arrows denote the3–5 A˚ shift of the green domain I
toward the top left of the figure and the7 A˚ translation of the N-terminal helix described in the text. A, B, and C loops of the bound ligand are labeled. The upper
inset details s-dEGFRDV side chains that interact with SpitzEGF, highlighting significant changes. The lower inset gives a similar view of domain III interactions,
which are only modestly changed. Residues underlined (E400, S401, H433, and E460) are mentioned in the text.
(B) Analogous overlay of the two bound ligands in the human (EGF)2,(s-hEGFRDIV)2 dimer from Figure 1B (Ogiso et al., 2002), illustrating similarity of the two
binding sites. Most side chains that contact bound ligand overlay very well in this superimposition.classes of binding site (or negative cooperativity) can be de-
tected in studies of SpitzEGF association with the isolated dEGFR
extracellular region. We linked s-dEGFR molecules via their flex-
ible C termini to a solid support to approximate their arrange-
ment at the cell surface while allowing dimerization. An AviTag
sequence was introduced (via an unstructured linker) at the
s-dEGFR C terminus to allow enzymatic biotinylation of the
protein and its capture on the surface of streptavidin-coated
96-well plates (see Experimental Procedures). SpitzEGF was
labeled with Alexa Fluor 488 to monitor its binding to surface-
bound s-dEGFR. The representative binding curve in Figure 3A
cannot be fit satisfactorily with a simple hyperbola, but fits well
to the Hill equation (red curve) with a low Hill coefficient (nH) of
0.31 that suggests negative cooperativity (the mean nH value
for all experiments was 0.38 ± 0.07, with a microscopic dissoci-
ation constant of 49.5 nM). Transformation of these data into
a Scatchard plot (Figure 3B) also reveals characteristic
concave-up curvature of the sort seen for human EGF binding
to its intact receptor at the cell surface. Parallel experiments
using a nondimerizing s-dEGFR mutant confirm that this
behavior requires s-dEGFR dimerization, and showed simple
hyperbolic binding curves (Figure 3C) and linear Scatchard plots
(Figure 3D) with a best-fit nH value of 1.02 (0.97 ± 0.1 over all
experiments) and a KD value of 0.92 mM.Our studies of SpitzEGF binding to dimerization-competent
s-dEGFR that has been purified to homogeneity are consistent
with the negative cooperativity seen for human EGF binding to
its intact cell-surface receptor (Macdonald and Pike, 2008;
Wofsy et al., 1992). Importantly, whereas isolating the human
EGFR extracellular region abolishes Scatchard plot curvature
(Lax et al., 1991; Lemmon et al., 1997; Livneh et al., 1986; Odaka
et al., 1997), our results show that this is not the case for
Drosophila EGFR. Concave-up Scatchard plots do not prove
negative cooperativity, however. Indeed, the curves in Figures
3A and 3B can alternatively be fit by assuming the superposition
of two hyperbolae that correspond to distinct (and independent)
classes of binding site—as has traditionally been done for EGF
binding to its cell-surface receptor. In such a fit for Figures 3A
and 3B, a high-affinity site (KD 4.7 nM) could account for
65% of the saturated SpitzEGF-binding signal, and an indepen-
dent lower-affinity class of sites (KD 1.3 mM) could account for
the rest. It seems unlikely thatmolecular heterogeneity is respon-
sible for the Scatchard plot curvature seen for s-dEGFR. Indeed,
these experiments were performed with highly purified protein.
Moreover, data in Figures 3C and 3D for dimerization-defective
s-dEGFRdim-arm argue that dimerization of the dEGFR extracel-
lular region is required for Scatchard plot curvature. Taken
together, these findings support the hypothesis that (as forCell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc. 571
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Figure 3. SpitzEGF Binding to s-dEGFR Yields Curved
Scatchard Plots
(A) Experimental data for binding of fluorescently labeled Spit-
zEGF to biotinylated s-dEGFR are well fit by the Hill equation
with a Hill coefficient (nH) of 0.31 (red curve), but not a simple
hyperbola (black). The inset shows saturation at >6 mM
SpitzEGF. Data are representative of over six independent
experiments.
(B) Scatchard transformation of binding data shown in (A). The
characteristic concave-up curvature is fit well by the Hill equa-
tion (nH = 0.31)—suggesting negative cooperativity.
(C) Data for fluorescent SpitzEGF binding to a dimerization-
defective s-dEGFR variant (s-dEGFRdim-arm) are well fit by
a simple hyperbolic binding curve (black) or by the Hill equa-
tion with Hill coefficient of 1.02 (dashed red curve) , suggesting
no cooperativity. Data are representative of over six indepen-
dent experiments.
(D) Scatchard transformation of data shown in (C) yields
a straight line, arguing that s-dEGFR dimerization is required
for negative cooperativity.EGF binding to hEGFR) the binding curves in Figures 3A and 3B
represent negatively cooperative binding of SpitzEGF to s-dEGFR
dimers, as suggested independently by the features of the asym-
metric (SpitzEGF)2,(s-dEGFRDV)2 dimer structure (and binding-
site inequivalence) discussed above. It is also important to
note that, both for s-dEGFR in our studies (Figure 3) and for intact
EGFR in cells (Macdonald and Pike, 2008), dimerization is
required for the appearance of high-affinity ligand binding and
for the manifestation of negatively cooperative ligand binding.Half-of-the-Sites Reactivity in a Spitz,s-dEGFRDV
Crystal Structure
Intriguingly, we also obtained evidence for half-of-the-sites reac-
tivity—the extreme of negative cooperativity—in crystallo-
graphic studies of s-dEGFRDV bound to a variant of SpitzEGF
(SpitzEGFDC) with a C-terminal truncation that reduces its affinity
for the receptor by 12-fold (Figure S3). Crystals that diffracted
to 3.4 A˚ grew from a 1:1.2 mixture of s-dEGFRDV and
SpitzEGFDC, and molecular replacement (MR) identified excellent
solutions for two s-dEGFRDV molecules in the asymmetric unit.
One was found using unligated s-dEGFRDV (or the right-hand
molecule in Figure 1A) as the search model. The other could
only be found in MR searches using the left-hand s-dEGFRDV
molecule from Figure 1A in which domains I and III are wedged
apart. Unfortunately, a marked anisotropy in all data sets made
full refinement of this structure impossible. We therefore used
only rigid-body refinement, treating each domain of the two s-
dEGFRDVmolecules as an independent body (see Experimental
Procedures). For domains I and III, this seemswell justified by the
absence of ligand-induced structural changes in the individual
domains of dEGFR or other ErbB receptors (Ferguson, 2008).
For domains II and IV, major structural changes may be missed
with this approach—but we do not expect them.
The rigid-body refined structure of the SpitzEGFDC,s-
dEGFRDV complex (Figure 4A) suggests a dimer with the572 Cell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc.same asymmetric arrangement of receptor molecules as seen
in the (SpitzEGF)2,(s-dEGFRDV)2 dimer discussed above, despite
the fact that the crystal packing is quite different in the two
cases. Most importantly, whereas one receptor molecule
showed clear electron density for bound ligand in 2Fo  Fc
maps (Figure 4B), the other showed none (Figure 4C)—even at
very low contour levels. The absence of ligand from this second
site cannot be explained by competing crystallization contacts.
Thus, SpitzEGFDC appears to induce the formation of a singly
ligated asymmetric s-dEGFRDV dimer in these crystals, de-
picted in Figure 4A. The left-hand (ligated) molecule in
Figure 4A has the same conformation as the left-hand molecule
in the (SpitzEGF)2,(s-dEGFRDV)2 dimer in Figure 1A, with
domains I and III wedged apart by the bound SpitzEGFDC. The
right-hand molecule in Figure 4A has the same conformation
as unligated s-dEGFRDV, and its binding site is empty (or at least
has very low occupancy). In parallel studies with Vein, a weak
dEGFR activator (Schnepp et al., 1998) with binding affinity
even lower than that of SpitzEGFDC (data not shown), we deter-
mined a 3.4 A˚ rigid-body-refined structure that also shows
a singly occupied asymmetric dimer. These apparently singly
ligated s-dEGFRDV dimers suggest half-of-the-sites reactivity,
where binding of SpitzEGFDC (or VeinEGF) to one site in the
s-dEGFRDV dimer prevents (or greatly impairs) ligand binding
to the second site.Remodeling of the s-dEGFR Dimer Interface upon
Ligand Binding
Unlike its human counterpart, the dEGFR extracellular region
dimerizes even in the absence of ligand, albeit weakly
(KD 40 mM). Moreover, unligated s-dEGFRDV crystallizes as
a symmetric (crystallographic) dimer, illustrated in Figure 5A
(Alvarado et al., 2009). The interface of this symmetric dimer
involves only the domain II dimerization arm, and the N-terminal
parts of domain II are splayed apart (Figures 5A and 5B). The
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Figure 4. Half-of-the-Sites Reactivity in s-dEGFRDV
(A) Crystal structure of an s-dEGFRDV dimer bound to SpitzEGFDC. Ligand is
bound to the left-handmolecule in which domains I and III are ‘‘wedged’’ apart,
but not the right-hand receptor molecule, which structurally resembles unli-
gated s-dEGFRDV. SpitzEGFDC lacks six amino acids from its C terminus,
and binds s-dEGFRDV with apparent KD = 4.37 ± 0.26 mM, 12-fold weaker
than the value of 368 ± 23 nM measured for SpitzEGF (Figure S3).
(B) Electron density is shown from a 2Fo  Fc map (blue) contoured at 1.0s,
calculated with model phases from the receptor molecules alone. In the region
corresponding to the left-hand binding site in (A), clear density for bound ligand
is seen. Ca traces for domains I and III are shown in blue and yellow, respec-
tively, in the density and the small part of domain IV seen is colored red.
(C) By contrast, the 2Fo  Fc map suggests no density for bound ligand in the
region corresponding to the right-hand binding site in (A). This binding site
appears to be vacant in crystals of a SpitzEGFDC,(s-dEGFRDV)2 dimer.total surface area buried in the unligated dimer interface is just
2262 A˚2.
Binding of SpitzEGF (or SpitzEGFDC) enhances s-dEGFR dimer-
ization by approximately 30-fold (Alvarado et al., 2009), associ-
ated with an increase of more than 50% in the surface area
buried at the dimer interface (to 3396 A˚2). This large expansion
of the interface arises primarily from direct contacts between
the domain II amino-terminal regions that are seen only in the
asymmetric ligand-induced dimer (Figure 5C). In binding to the
left-hand molecule in Figure 5C, SpitzEGF (magenta) has wedged
itself between domain I (blue) and domain III (yellow), causing
domain II (green) to become distorted or ‘‘bent.’’ The amino-
terminal part of domain II in the left-hand molecule effectively
‘‘collapses’’ onto its unaltered counterpart (gray) in the right-
hand molecule, creating an additional set of intimate interfacial
contacts (Figure 5D). The equivalent domain II regions are
splayed apart in the symmetric unligated s-dEGFRDV dimer
(Figure 5B), presumably restrained by direct interactions
between domains I and III of the receptor (Figure S1) that we
previously suggested may play an autoinhibitory role (Alvarado
et al., 2009). The additional >1000 A˚2 of surface area buried in
the asymmetric dimer is likely to account for the 30-fold
(2 kcal/mol) increase in dimerization affinity observed upon
ligand binding.
Formation of the more extensive asymmetric dimer interface
seen in Figure 5D arises largely from a ligand-induced kink (of
12) between modules m4 and m5 of domain II (marked with
an arrow in Figure 5B). Modules m2, m3, and m4 from domain
II of the left-hand molecule (green) dock onto the domain II
surface (gray) of the neighboring molecule in the dimer, without
substantially altering the dimerization arm contacts (mediated
by module m5). Side chains from Q189 and R201 (in module
m2), plus H205 (in module m3) of the ligand-bound receptor
molecule, make polar contacts across the dimer interface.
Several additional side chains, including those from P188 and
P200 (from module m2) plus L206 and F207 (from module m3)
also make van der Waals contacts with the opposing domain II
in Figure 5D. Modules m2, m3, and m4 bury a combined surface
of 1160 A˚2 in the asymmetric s-dEGFRDV dimer interface (34%
of the total interface), allowing an intimate set of receptor/
receptor contacts to extend along much of the length of domain
II in this dimer. Interestingly, Q189, P200, and H205 are
conserved in hEGFR and human ErbB3. Q189 is also conserved
in hErbB4, P200 in ErbB2, and H205 in hErbB2 and hErbB4.
R201, L206, and F207 are not conserved in the human receptors.
Whereas the domain II amino termini make intimate contacts
across the interface of the (SpitzEGF)2,(s-dEGFRDV)2 dimer,
they contribute little to receptor/receptor contacts in the
symmetric human sEGFR dimer (Figure 1B), burying just
476 A˚2 (with no contribution from m4). Dimerization arm-medi-
ated interactions are very similar in both Drosophila and human
sEGFR dimers (Garrett et al., 2002; Ogiso et al., 2002). However,
additional differences between dEGFR and hEGFR are seen for
interactions involving the carboxy-terminal part of domain II
(modules m7 and m8). These modules make no direct contact
across the interface in ligated human sEGFR dimers, whereas
in s-dEGFRDV they interact more extensively in the unligated
dimer than in the ligand-induced dimer. As a result (and becauseCell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc. 573
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C Figure 5. Ligand Binding Promotes an
Extensive Asymmetric Dimerization Inter-
face
(A) Crystallographic dimer of unligated
s-dEGFRDV reported previously (Alvarado et al.,
2009), shown surface rendered with individual
domains colored as in Figure 1A.
(B) Close-up of the unligated s-dEGFRDV dimer in
the domain II region. Disulfide-bonded modules
m2–m8 are labeled, as are selected residues that
interact across the ligated dimer interface in (D).
An arrow marks the location between modules
m4 and m5 of the ligand-induced kink (of 12)
that allows the amino-terminal region of the left-
hand domain II to ‘‘collapse’’ into its right-hand
counterpart in (D).
(C) Surface-rendered asymmetric (SpitzEGF)2,
(s-dEGFRDV)2 dimer, with individual domains
and ligand colored as in (A).
(D) Domain II region close-up of the (SpitzEGF)2,
(s-dEGFRDV)2 dimer. Disulfide-bonded modules
m2, m3, and m4 from the left-hand molecule
(green) have ‘‘collapsed’’ onto their counterparts
in the right-hand molecule (gray), burying 1160 A˚2
in an intimate domain II interface. Dimerization
arm-mediated contacts are largely unaltered.of changes in the domain II/III relationship), ligand binding actu-
ally increases the distance separating the two copies of domain
IV in the s-dEGFRDV dimer by approximately 24 A˚ (Figures 5A
and 5C); that is, ligand binding actually appears to drive apart
domains IV of the two receptor molecules in the transition from
a putative ‘‘preformed dimer’’ (Figure 5A) to a ligand-activated
form (Figure 5C).A Structural Model for Negative Cooperativity
in an EGFR Extracellular Region
Levitzki et al. (1971) pointed out four possible sources for half-of-
the-sites reactivity in dimeric enzymes. In the first, the two
ligand-binding sites are adjacent such that occupation of one
site directly occludes the second. This cannot explain negative
cooperativity in EGFR, where the two binding sites in the dimer
are more than 50 A˚ apart. Two other models require nonidentical
binding sites in unligated dimers that arise either from asym-
metric dimerization without ligand or from the existence of
distinct subunit classes—neither of which are relevant for
dEGFR. The fourth and final model involves a symmetric unli-
gated dimer with two identical binding sites. Ligand binding to
one of these sites induces conformational changes that promote
asymmetry in the dimer, and restrain the vacant binding site so
that its affinity for ligand is reduced. A model of this sort may
explain the ligand-binding properties of dEGFR, as illustrated
by the gallery of structures presented in Figure 6.
Before interacting with SpitzEGF, the ligand-binding sites are
identical in crystallographic preformed dimers, and presumably
monomers, of s-dEGFR (Figure 6A). Ligand may bind to either
species. In either case, the first (highest-affinity) binding event
yields the singly ligated, asymmetric SpitzEGF,(s-dEGFRDV)2
dimer shown in Figure 6B. High-affinity ligand binding appears
to require receptor dimerization because the s-dEGFRdim-arm574 Cell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc.mutant shows only low-affinity SpitzEGF binding (Figure 3).
Indeed, formation of the asymmetric interface in Figure 5D will
facilitate domain II bending in the left-hand molecule, in turn
promoting the wedging apart of domains I and III by the first
ligand that binds—and enhancing its affinity.
In the asymmetric s-dEGFRDV dimer formed after the first
(high-affinity) binding event (Figure 6B), domain II in the unoccu-
pied receptor is subjected to a new set of structural restraints. It
can no longer bend to allow SpitzEGF to wedge itself fully into the
unoccupied ligand-binding site without disrupting the intimate
asymmetric interface between amino-terminal parts of domain
II shown in Figure 5D. This interface therefore restricts binding
of ligand to the right-hand (unligated) receptor in Figure 6B.
When a second ligand molecule does bind to the empty site in
this dimer, two scenarios (at the extremes) are possible:
(1) The asymmetric dimerization interface seen in Figure 6B
may be left intact.With the conformation of domain II fixed
in the right-handmolecule so that it cannot bend, it will not
be possible for a ligand to wedge domains I and III apart
upon binding. This restriction will necessitate binding of
ligand to an unaltered (suboptimal) site—as seen for
SpitzEGF binding to the red binding site in Figure 2A.
This would explain the reduced binding affinity of the
second (right-hand) site in the s-dEGFR dimer.
(2) Alternatively, ligand binding to the second site in the dimer
could wedge domains I and III apart exactly as in the first
ligand-binding event. The resulting domain II distortion
would break the ‘‘extra’’ contacts in the asymmetric
domain II/domain II interface shown in Figure 5D, effec-
tively ‘‘resymmetrizing’’ the dimer. The work required to
disrupt the asymmetric domain II/domain II interface will
reduce the effective affinity of the second site for ligand.
B C
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Figure 6. Model for Negatively Cooperative Ligand Binding to s-dEGFR
(A–C) Structures and cartoons describe a model for negatively cooperative ligand binding to s-dEGFRDV. Domains (and ligand) are colored as in Figure 1.
(A) Binding of a single ligand either to ‘‘preformed’’ s-dEGFRDV dimers (which have two identical binding sites) or to s-dEGFRDV monomers yields the singly
ligated dimer shown in (B).
(B) Singly ligated s-dEGFRDV dimers are asymmetric. Binding of SpitzEGFDC to the left-hand molecule wedges apart domains I and III (blue and yellow), and thus
‘‘bends’’ domain II (green) such that it collapses against its counterpart (gray) in the neighboring right-hand molecule, as in Figure 5D.
(C) A second SpitzEGF binds to the singly ligated dimer, and occupies the binding site in the right-hand molecule with no change in s-dEGFR conformation. The
intimate dimer interface in (B) restrains domain II in the right-handmolecule, so that domains I and III cannot readily be wedged apart. Thus, the binding event that
occurs in going from (B) to (C) involves a compromised set of ligand/receptor interactions as described in Figure 2A, reducing binding affinity (and retaining asym-
metry in the doubly ligated dimer).
(D) The dimer of human s-hEGFRDIV formed upon EGF binding is symmetric (Ogiso et al., 2002), with both ligands bound in the same manner (Figure 2B).
A symmetric dimer of this sort would form following ligand binding to the dimer in (B) if ligand/receptor contacts were maximized at the expense of contacts
in the dimerization interface.The first of these possibilities is likely to explain why asymme-
try is maintained in the (SpitzEGF)2,(s-dEGFRDV)2 dimer even
after binding of the second ligand (Figure 6C). The energetic
cost of disrupting the asymmetric dimer interface in Figure 6B
presumably outweighs the gain in ligand/receptor interactions
that can be achieved by wedging apart domains I and III to opti-
mize the second binding site. The second SpitzEGF molecule
therefore binds without altering the s-dEGFRDV structure, and
occupies a compromised binding site (red in Figure 2A) with
reduced contact area and fewer predicted hydrogen bonds
(and therefore lower affinity). The 12-fold-reduced receptor-
binding affinity of SpitzEGFDC appears to prevent this ligand
variant from occupying the compromised binding site altogether
in our crystals, explaining the half-of-the-sites reactivity seen in
the SpitzEGFDC,(s-dEGFRDV)2 dimer (Figure 4).The second of the possibilities outlined above is likely to
explain the symmetry of the fully occupied human s-EGFRDIV
dimer illustrated in Figure 6D (Ogiso et al., 2002). If domain II-
mediated interactions in the asymmetric (singly ligated) dimer
are weaker in human EGFR than in Drosophila, they will be dis-
rupted more readily by binding of a second ligand molecule.
There are several reasons to suspect that these interactions
are indeed weaker in human EGFR than in its Drosophila coun-
terpart. Whereas the isolated extracellular region of dEGFR
retains negatively cooperative ligand binding, contributions
from the intracellular region are essential in the case of human
EGFR (Livneh et al., 1986; Macdonald-Obermann and Pike,
2009). This argues that cytoplasmic domain interactions are
required to stabilize the singly ligated intact human EGFR dimers
required for negatively cooperative EGF binding, or indeed ErbBCell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc. 575
receptor heterodimers (Figure S4). Unlike itsDrosophila counter-
part, isolated s-hEGFR does not form singly ligated dimers in
solution and does not exhibit negatively cooperative ligand
binding (Lemmon et al., 1997; Odaka et al., 1997). However,
negative cooperativity can be recapitulated in solution by fusing
s-hEGFRDIV to a dimeric IgG Fc domain (Adams et al., 2009)—
as also described for the insulin receptor (Bass et al., 1996;
Hoyne et al., 2000). Studies of such artificial dimers may be
needed in order to examine structural details of the singly ligated
hEGFR dimer inferred from cellular studies. It is also important to
note that the intracellular regions of human EGFR and ErbB4
form asymmetric dimers (Jura et al., 2009; Qiu et al., 2008;
Red Brewer et al., 2009), which may contribute to the stabiliza-
tion of asymmetric, singly ligated dimers of the intact receptors.
Residues in this intracellular dimer interface are not conserved in
dEGFR, consistent with an increased reliance on extracellular
interactions for negative cooperativity in Drosophila.
Implications for the High- and Low-Affinity Binding Sites
for Human EGF
Our studies suggest that the proposed high-affinity and low-
affinity classes of EGF-binding site at the cell surface do not
reflect distinct EGFR populations. Rather, the characteristic
curved Scatchard plots reflect negatively cooperative EGF
binding to a single type of receptor species. In the binding
scheme illustrated in Figure 6, the first binding event—leading
to the singly ligated dimer in Figure 6B—could be considered
as the high-affinity site, and the second (leading to Figure 6C)
as the low-affinity site. Restraints imposed on the second
binding site in an asymmetric, singly ligated dimer can explain
negatively cooperative ligand binding in a model that closely
resembles mechanisms of negative cooperativity and half-of-
the-sites reactivity reported for other multisubunit enzyme
systems (Koshland, 1996; Levitzki et al., 1971).
We suggest that studies of the isolated human EGFR extracel-
lular region have failed to recapitulate key receptor/receptor
interactions required for its allosteric regulation. Intact human
EGFR is reported to self-associate to some extent even in the
absence of ligand (Chung et al., 2010; Saffarian et al., 2007),
and is thought to form singly ligated, asymmetric dimers required
for negatively cooperative ligand binding at the cell surface
(Macdonald and Pike, 2008). Both of these properties are lost
when the human EGFR extracellular region is studied in isolation
(Lemmon et al., 1997; Odaka et al., 1997). A similar problem
exists for the insulin receptor, where negative cooperativity in
insulin binding is completely abolished when the extracellular
region of the receptor is released from the membrane surface
(De Meyts and Whittaker, 2002). By contrast, the isolated extra-
cellular region of the Drosophila EGFR appears to maintain the
self-association and allosteric properties of the intact receptor,
allowing our studies of s-dEGFR to provide serendipitous insight
into the mechanism of its allosteric regulation and structural
basis for negative cooperativity.
Conclusions and Perspectives
The origin of concave-up Scatchard plots seen for EGF binding
to its cell-surface receptor over the past three decades has
been contentious. The molecular nature of the high-affinity and576 Cell 142, 568–579, August 20, 2010 ª2010 Elsevier Inc.low-affinity EGF-binding sites suggested by these curves has
also been a subject of significant debate, although recent work
suggests that they reflect negative cooperativity rather than
distinct classes of site (Macdonald and Pike, 2008). The studies
described here provide a structural basis for understanding
negative cooperativity in ligand binding to an EGF receptor.
Our analysis suggests that high- and low-affinity binding sites
for ligand do exist, but that they occur in the same dimeric
receptor complexes and arise from negative cooperativity rather
than from distinct populations or ‘‘classes’’ of receptor.
If the curved Scatchard plots seen in studies of cell-surface
EGF binding reflect negative cooperativity, how can apparent
functional and structural differences between the presumed
high-affinity and low-affinity classes of EGF receptors be ex-
plained? Early studies with antibodies reported to interfere only
with high-affinity or low-affinity sites, respectively, concluded
that the high-affinity subclass is necessary for early signaling
responses to EGF (Bellot et al., 1990; Defize et al., 1989). More-
over, the route of EGFR internalization from the cell surface
depends on the concentration of ligand used to activate the
receptor, suggesting that the high-affinity and low-affinity
classes of receptor may be subjected to different endocytic
mechanisms (Sorkin andGoh, 2009). At low EGF concentrations,
EGFR internalization is primarily clathrin mediated, whereas cla-
thrin-independent mechanisms appear to dominate when very
high EGF concentrations are applied. The negative cooperativity
model ofMacdonald and Pike (2008) suggests that binding of the
second ligand to an EGFR dimer reduces the affinity of the two
receptors for one another by 10-fold. Indeed, our s-dEGFR
structures show how the second ligand-binding event must
either compromise ligand/receptor or receptor/receptor
contacts (Figure 6). A weakened, doubly occupied, EGFR dimer
could behave quite differently from one with only one site occu-
pied—with altered dynamics and interaction (and dimer-
exchange) properties that might alter specificity, degree of
autophosphorylation, mechanism of internalization, and other
outcomes.
Differences in the signaling properties of singly and doubly
occupied receptors may also explain the distinct biological
outcomes when cells are treated with different agonists for the
same ErbB receptor (Wilson et al., 2009) or different concentra-
tions of ligand. For example, EGFR agonists with low receptor-
binding affinities (amphiregulin, epiregulin, and epigen) might
induce the formation of only (or primarily) singly ligated dimers,
whereas EGFR agonists with high affinity for the receptor
(EGF, TGFa, betacellulin, and HB-EGF) should be able to occupy
both binding sites in the receptor dimer if present at sufficiently
high concentrations. As a result, the receptor may be activated
(and internalized—and ultimately deactivated) differently in
response to the two ligand classes. A difference in signaling
outcomes of this sort may be very important where EGFR ligands
function as morphogens. Gradients of ligands for the Drosophila
EGFR (Spitz, Keren, Gurken, and Vein) function in tissue
patterning in many developmental programs in D. melanogaster
(Shilo, 2005). It is not clear how different concentrations of these
ligands in morphogen gradients can induce different cell fates,
which is crucial for ‘‘interpreting’’ the gradients. Our work
suggests one possibility. At the gradient peak, where ligand
concentrations are high, dEGFR dimers will be fully occupied
(with two ligands bound per dimer). By contrast, at the tail end
of the morphogen gradient where ligand concentrations are
low, only high-affinity sites will be occupied in the receptor
dimers—yielding singly ligated dEGFR dimers. If the doubly
and singly ligated dimers have different signaling properties
and internalization routes, distinct cell fates could be induced
in the two regimes of receptor activation. This graded occupa-
tion of the two binding sites in the EGFR dimer would be
substantially lessened in a noncooperative system.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Histidine-tagged s-dEGFR proteins were produced by secretion from baculo-
virus-infected Sf9 cells and purified exactly as described (Alvarado et al.,
2009). An AviTag-encoding sequence was included after the C-terminal histi-
dine tag (see Extended Experimental Procedures) for biotinylating protein for
fluorescent ligand binding assays. SpitzEGF and SpitzEGFDC were secreted
from stably transfected Drosophila Schneider-2 (S2) cells and purified as
described in Extended Experimental Procedures.Crystallography
Crystals of the (SpitzEGF)2,(s-dEGFRDV)2 dimer were obtained using the
hanging-drop method, mixing equal volumes of protein (75 mM s-dEGFRDV,
90 mM SpitzEGF) and reservoir solution (1.5 M NaKPO4 [pH 6.9] with 4%
t-butanol) and equilibrating over this reservoir at 21C. Crystals grew to
0.5 3 0.3 3 0.15 mm, and were cryoprotected by adding stepwise to the
drop sodium malonate (pH 6.9) (mixed with reservoir solution) until a sodium
malonate concentration was reached (1.7–2 M) that allowed the solution
to freeze clear. Frozen crystals diffracted to 3.2 A˚ resolution at Cornell High
Energy Synchrotron Source (CHESS) beamline F1, and belonged to space
group P212121 with unit cell dimensions a = 118.2 A˚, b = 124.2 A˚, c = 186.5 A˚
(Table S1). The asymmetric unit contained two s-dEGFRDV molecules, with
a solvent content of 70.1%.
SpitzEGFDC,(s-dEGFRDV)2 dimer crystals (up to 0.53 0.23 0.2 mm) grew at
21C using the hanging-drop method from a mixture of purified s-dEGFRDV
(50 mM) and SpitzEGFDC (60 mM) and reservoir solution (11% PEG 20,000,
0.1 M HEPES [pH 7.4] with 3% n-propanol). Prior to freezing in liquid nitrogen,
crystals were cryoprotected by adding ethylene glycol (in 13% PEG 20,000
and 0.1 M HEPES [pH 7.4]) stepwise to a final concentration in the drop of
30% (v/v). Crystals diffracted to 3.4 A˚ resolution at Advanced Photon Source
(APS) beamline 23-ID-D, and belonged to space group P212121 with unit cell
dimensions a = 73.8 A˚, b = 120.2 A˚, c = 274.7 A˚ (Table S1). With one
receptor/ligand (2:1) complex in the asymmetric unit, solvent content is
68.7%. Diffraction data for SpitzEGFDC,(s-dEGFRDV)2 crystals were visibly
anisotropic, and were subjected to ellipsoidal truncation to 4 A˚ in the a* axis
and 3.5 A˚ in the b* and c* axes, and anisotropic scaling (http://www.
doe-mbi.ucla.edu/sawaya/anisoscale) (Strong et al., 2006).
Data were processed with the program HKL2000 (Otwinowski and Minor,
1997), and structures were solved by molecular replacement (MR) using the
programPhaser (CCP4, 1994). AnMR solution for onemolecule in the receptor
dimer was found readily for both datasets using coordinates from unligated
s-dEGFRDV (Protein Data Bank [PDB] ID code 3I2T) as the search model.
The resulting maps showed clear electron density for the second receptor
molecule and its bound SpitzEGF or SpitzEGFDC molecule, allowing domains I
and III to be placed and domains II and IV to be fit. Initial fitting focused on
the SpitzEGFDC,(s-dEGFRDV)2 dimer structure, early models of which were
used to improve model phases for the (SpitzEGF)2,(s-dEGFRDV)2 complex.
Cycles of manual building/rebuilding using Coot (Emsley and Cowtan, 2004)
were alternated with rounds of refinement employing REFMAC and solvent
flattening with the program DM (CCP4, 1994), plus composite omit maps
calculated with CNS (Bru¨nger et al., 1998). TLS refinement (Winn et al.,
2001) was used in later stages, using REFMAC (CCP4, 1994), with anisotropicmotion tensors refined for each of the receptor domains and bound ligand
molecules.
Although initial maps for the SpitzEGFDC,(s-dEGFRDV)2 complex showed
clear density for the second receptor molecule and its bound SpitzEGFDCmole-
cule, the quality of the electron density remained poor throughout large areas
of this structure during refinement and phase combination, particularly in
domains I and III. We therefore re-solved this structure byMR using the refined
(receptor-only) coordinates of each receptor molecule in the (SpitzEGF)2,
(s-dEGFRDV)2 complex as independent search models in sequential steps.
Both receptor molecules were found readily with Phaser (CCP4, 1994), and
clear SpitzEGFDC density in only one binding site (Figure 4) allowed its place-
ment as a rigid body. The coordinates for the MR search model (plus placed
ligand) were then subjected only to rigid-body refinement, with each receptor
domain (and single placed ligand) as an independent body. R/Rfree values of
41.0/42.7 were obtained (Table S1). Structural figures were generated using
PyMOL (DeLano, 2002).
Receptor Biotinylation and Fluorescent Ligand-Binding Assays
Purified s-dEGFR and s-dEGFRdim-arm were biotinylated, and SpitzEGF was flu-
orescently labeled with Alexa Fluor 488 using standard procedures detailed in
Extended Experimental Procedures. Biotinylated s-dEGFR was captured in
Reacti-Bind streptavidin-coated 96-well plates (Pierce) in Tris-buffered saline
(TBS) plus 0.5% (w/v) bovine serum albumin (TBS-B). Labeled SpitzEGF in TBS-
B was then added at a range of concentrations, both to wells with biotinylated
s-dEGFR protein and mock-treated wells, and agitated at 25C for 2 hr. Total
ligand fluorescence per well was then counted in a Tecan Safire-2 microplate
reader. The plate was then quickly washed with TBS-B, and the remaining
(bound) fluorescent ligand was measured. Specific binding was determined
by subtracting from the fluorescencemeasured for eachwell containing bound
s-dEGFR protein the background fluorescence measured for mock-treated
wells subjected to the same labeled SpitzEGF concentration. Background
was typically less than 10% of the binding signal for s-dEGFR experiments,
and less than 50% (at low ligand concentrations) for s-dEGFRdim-arm experi-
ments. Fluorescence values for (specifically) bound labeled (and free) SpitzEGF
were converted to picomoles using a standard curve generated by measuring
fluorescence of known labeled SpitzEGF concentrations.
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